Phase I trial of the targeted alpha-particle nano-generator actinium-225 (ac-225)-lintuzumab (anti-CD33; HuM195) in acute myeloid leukemia (AML) Meeting Abstract


Authors: Jurcic, J. G.; Rosenblat, T. L.; McDevitt, M. R.; Pandit-Taskar, N.; Carrasquillo, J. A.; Chanel, S. M.; Zikaras, K.; Frattini, M. G.; Maslak, P. G.; Cicic, D.; Larson, S. M.; Scheinberg, D. A.
Abstract Title: Phase I trial of the targeted alpha-particle nano-generator actinium-225 (ac-225)-lintuzumab (anti-CD33; HuM195) in acute myeloid leukemia (AML)
Meeting Title: 53rd Annual Meeting and Exposition of the American Society of Hematology (ASH)/Symposium on the Basic Science of Hemostasis and Thrombosis
Journal Title: Blood
Volume: 118
Issue: 21
Meeting Dates: 2011 Dec 10-13
Meeting Location: San Diego, CA
ISSN: 0006-4971
Publisher: American Society of Hematology  
Date Published: 2011-11-01
Start Page: 348
End Page: 349
Language: English
ACCESSION: WOS:000299597101039
PROVIDER: wos
Notes: --- - Meeting Abstract: 768 - 53rd Annual Meeting and Exposition of the American-Society-of-Hematology (ASH)/Symposium on the Basic Science of Hemostasis and Thrombosis - DEC 10-13, 2011 - San Diego, CA - "Source: Wos"
MSK Authors
  1. Michael R Mcdevitt
    117 Mcdevitt
  2. Joseph G Jurcic
    122 Jurcic
  3. Suzanne M Chanel
    28 Chanel
  4. Peter Maslak
    160 Maslak
  5. Steven M Larson
    736 Larson
Related MSK Work